{"filings":[{"id":125125,"accession_number":"0001493152-25-028361","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Annual meeting results: all five director nominees elected; auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David McWilliams (7,175,656 for, 452,124 abstain), Snehal Patel (7,408,074 for), Eric Rothe (7,184,827 for), F. Joseph Daugherty (7,337,720 for), Kenneth Hallock (7,313,167 for) elected.","Ratification of MaloneBailey LLP as auditor: 8,908,299 for, 31,459 against, 4,857 abstain.","Total shares represented: 8,944,615; quorum achieved.","Broker non-votes: 1,316,835 on director proposals; none on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141835,"accession_number":"0001641172-25-020843","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences dismisses RBSM, hires MaloneBailey as auditor effective July 19, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved dismissing RBSM LLP and engaging MaloneBailey LLP for fiscal 2025 audit.","RBSM's reports for 2024 and 2023 were unqualified; no disagreements on accounting or auditing matters.","Prior material weaknesses in internal control over financial reporting were discussed with RBSM and disclosed in earlier SEC filings.","RBSM provided a letter to the SEC, attached as Exhibit 16.1, agreeing with the Company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194801,"accession_number":"0001493152-24-050777","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Greenwich LifeSciences holds 2024 annual meeting; all director nominees elected, equity plan amendment approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees elected with majority support; no votes against, only abstentions and broker non-votes.","Ratification of RBSM as independent auditor for FY2024 approved: 9,224,694 for, 10,077 against, 2,644 abstain.","Amendment to 2019 Equity Incentive Plan to increase reserved shares from 1.5M to 4.0M approved: 8,067,672 for, 164,730 against.","Total shares represented at meeting: 12,848,165, constituting a quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229610,"accession_number":"0001493152-24-024035","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Greenwich LifeSciences raises ~$2.5M in private placement with CEO at $14.30/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Snehal Patel purchased 174,825 shares at $14.30 (June 12 closing price) for ~$2.5M gross proceeds.","Shares are restricted securities, no registration rights; closing expected June 18, 2024.","Net proceeds to be used for clinical development and working capital.","Private placement is exempt under Section 4(a)(2) and Rule 506 of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248137,"accession_number":"0001493152-24-007223","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2024-02-20T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences dismisses MaloneBailey; engages RBSM as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee approved dismissal of MaloneBailey and engagement of RBSM on Feb 14, 2024.","MaloneBailey informed of dismissal effective Feb 15, 2024; RBSM engaged for FY 2023 audit.","MaloneBailey's reports for 2021-2022 had no adverse opinion, disclaimer, or qualification.","No disagreements on accounting or audit scope during 2022-2023 or through Feb 14, 2024.","Material weaknesses in internal control over financial reporting were previously disclosed and discussed with both auditors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248136,"accession_number":"0001493152-24-006664","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2024-02-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences expands Phase III Flamingo-01 arm to 250 patients; European sites pending","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended continue as is; no serious adverse events related to GLSI-100 reported to date.","Non-HLA-A*02 open-label arm expanded from 100 to 250 patients per Steering Committee guidance.","European regulatory approval expected 2024; contracts for 105-120 sites in Spain, France, Germany, Italy, Poland.","First 3 commercial lots of GP2 completed in 2023; enough for ~200,000 doses; commercial vial filling planned 2024.","Phase II data review found potential recurrence in treated arm (Q4 2023); company states no material effect on study power."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265599,"accession_number":"0001493152-23-045048","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Greenwich LifeSciences stockholders elect five directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Total 8,232,391 shares voted, constituting a quorum.","All five director nominees elected: McWilliams (7,005,454 for), Patel (7,140,753), Rothe (7,034,141), Daugherty (7,139,876), Hallock (7,080,646).","Ratification of Malone Bailey, LLP as independent auditor approved: 8,210,833 for, 14,108 against, 7,449 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302133,"accession_number":"0001493152-23-012053","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2023-04-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Greenwich LifeSciences confirms FDA review of Phase IIb data, provides Flamingo-01 trial update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA reviewed Phase IIb clinical data before Flamingo-01 Phase III trial commencement.","First US sites activated in Q3 2022; patient enrollment and treatment ongoing since Q4 2022.","DTH skin tests and blood samples collected to assess immune response.","Company planning expansion of Flamingo-01 clinical trial into Europe.","Abstract and poster on Flamingo-01 design presented at AACR on April 17, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321807,"accession_number":"0001493152-23-007316","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Greenwich LifeSciences clarifies no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company confirms it does not hold cash deposits at Silicon Valley Bank.","Company confirms it holds no securities at Silicon Valley Bank.","No direct financial impact from SVB collapse is expected based on this disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339910,"accession_number":"0001493152-22-035047","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Greenwich LifeSciences annual meeting elects all five director nominees, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five nominees (McWilliams, Patel, Rothe, Daugherty, Hallock) elected with 8.4M-8.6M votes for each; ~818K broker non-votes.","Malone Bailey, LLP ratified as independent auditor for FY2022: 9,733,708 for, 15,043 against, 6,444 abstain.","Total 9,755,196 shares represented at meeting, constituting a quorum.","No material changes to board composition or governance disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357212,"accession_number":"0001493152-22-019051","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences enters $100M ATM equity offering agreement with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Open Market Sale Agreement with Jefferies LLC for at-the-market offering of common stock up to $100M.","Commission rate of up to 3.0% of gross proceeds; Jefferies gets customary indemnification.","Proceeds intended for general corporate purposes including GP2 clinical development, R&D, working capital.","No obligation to sell any shares; company can suspend offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357211,"accession_number":"0001493152-22-019038","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2022-07-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA removes clinical hold on Greenwich LifeSciences' Flamingo-01 Phase III trial","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA formally removed the clinical hold on July 11, 2022, allowing the Flamingo-01 Phase III trial to proceed.","Clinical hold was related to manufacturing and pharmacy process issues; company has addressed them with additional testing commitments.","Company has begun site initiation visits and will provide future updates on trial progress.","GLSI-100 is the drug candidate under development for breast cancer immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357210,"accession_number":"0001493152-22-019022","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2022-07-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA clinical hold on GLSI-100 Phase III Flamingo-01 remains; manufacturing data submitted, review ongoing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA placed clinical hold on Flamingo-01 trial for GLSI-100 (GP2) in HER2/neu positive patients, citing manufacturing issues.","Company completed manufacturing of three clinical lots of GP2 that meet release specifications; third lot made on commercial automated filling line.","FDA is reviewing manufacturing data and sent follow-up questions; company has responded.","Site initiation visits being scheduled to train clinicians and activate clinical sites.","No assurance when or if clinical hold will be released; risk factor supplemented."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412741,"accession_number":"0001493152-21-031573","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2021-12-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Greenwich LifeSciences holds 2021 annual meeting; reelects five directors and ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All five director nominees (McWilliams, Patel, Rothe, Daugherty, Hallock) elected with strong support; broker non-votes of 568,923 each.","Ratification of Malone Bailey, LLP as independent auditor received 10,523,113 For, 6,200 Against.","Quorum of 10,540,382 shares represented at meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412740,"accession_number":"0001493152-21-031170","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2021-12-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences reports 5-year GP2 Phase IIb data: baseline immune response predicts recurrence","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22.8% of 145 patients had positive baseline DTH response to GP2; 24.2% recurrence rate over 5 years (median 99 days).","Patients without baseline response had 12.5% recurrence rate with median time to recurrence of 438 days.","HER2+ patients completing GP2 primary series showed 100% DFS vs 89.4% for placebo (p=0.0338) over 5 years.","GP2 treatment was well tolerated with no serious adverse events attributed to GLSI-100.","Company plans Phase III trial in 2022 and exploration of GP2-specific CAR-T cell candidates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412739,"accession_number":"0001493152-21-027743","cik":1799788,"company_name":"Greenwich LifeSciences, Inc.","ticker":"GLSI","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Greenwich LifeSciences updates corporate presentation; highlights GP2 Phase IIb data and partnership discussions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Combined analysis of 5-year Phase IIb data shows no recurrences in HER2/neu 3+ patients receiving 6 primary injections (p=0.0338).","Company reports interest from large pharma, regional pharma, and biotech investors regarding licensing and collaboration.","Discussions include possible GP2 licensing, new investment banking partners, Phase III trial collaboration, and European expansion.","GP2 treatment was well tolerated with no serious adverse events across 138 patients in 4 clinical trials.","Phase III clinical trial planned with similar treatment regime to Phase IIb."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":384601994.1211085,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}